Peanut Hypersensitivity
21
1
3
16
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
63%
10 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (21)
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Boiled Peanut Oral Immunotherapy
Boiled Peanut Immunotherapy for the Treatment of Peanut Allergy
FARE Peanut SLIT and Early Tolerance Induction
Peanut Oral Immunotherapy in Children
PEAnut Anaphylaxis Predictors
Mechanisms Underlying Peanut Allergic Reactions in TRACE Peanut Study Participants: Extension Study
A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
Oral Immunotherapy (OIT) for Peanut Allergy
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
An Observational Study of Childhood Food Allergy
Oral Peanut Immunotherapy for Peanut Allergic Patients
The Effect of Extrinsic Factors on Food Allergy
Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g